TTK Healthcare Q1FY27: PAT +64% YoY (~24% adjusted), revenue up 14%
PAT +63.69% YoY · revenue +13.75% · margins expanding
₹257.56 Cr
+13.75% YoY
₹21.28 Cr
+63.69% YoY
7.76%
+2.4pp YoY
₹15.06
TTK Healthcare's standalone revenue came in at ₹257.56 Cr, up 13.7% YoY and 18.2% QoQ, with PAT of ₹21.28 Cr, up 63.7% YoY but down 2.2% QoQ. Basic EPS was ₹15.06, against ₹9.20 a year ago and ₹15.40 last quarter. The company carries no subsidiaries, so standalone is the sole basis for these results.
Q1 FY-2027 vs prior quarters
The headline YoY PAT jump is materially inflated by a one-off: Note 3 discloses the company invoiced ₹7.02 Cr (₹701.85 lakh) of USAID export orders against Protective Devices inventory that had been fully written off in FY25, meaning near the entire amount drops to pre-tax profit. Stripping this out at the quarter's 26.3% effective tax rate, adjusted PAT growth is ~24% YoY versus 13.7% revenue growth — still profit outgrowing revenue, but far short of the 64% reported figure. Net margin improved to 7.76% from 5.32% YoY (though it compressed from 9.23% in Q4FY26), while operating margin rose to 5.72% from a depressed 1.18% a year ago. The Protective Devices segment was the swing factor, moving to a ₹6.13 Cr segment profit from a ₹5.44 Cr loss in Q1FY26 — the single largest driver of the YoY improvement, substantially aided by the one-off order. Animal Welfare segment profit, by contrast, fell to ₹1.15 Cr from ₹2.34 Cr YoY despite segment revenue growth, partially offsetting the Protective Devices strength.
The stock went into the print at ₹1,123.4, up 23% over the past month of trading.
For context: this is the second-highest quarterly PAT of the last 6 quarters; revenue is at a 6-quarter high.
No formal Street consensus estimates or management guidance for this quarter were found on record or via web search — TTK Healthcare is thinly covered as a small-cap, so vsStreet and vsGuidance are marked unknown/none rather than assumed. The management press release furnished only the standard Regulation 30 board-outcome disclosure with no forward commentary to grade against. Separately, on July 23, 2026 the company signed a definitive agreement to sell its EVA and Good Home brands (Consumer Products segment) to Wipro Enterprises for ₹256 Cr against a net book value of just ₹0.70 Cr; the deal is expected to close by September 30, 2026 and its gain is not reflected in this quarter's numbers.
W1
Whether Protective Devices sustains profitability next quarter without the ~₹7.02 Cr one-off USAID inventory recovery that boosted Q1FY27
W2
Completion of the EVA & Good Home brand sale (₹256 Cr consideration, ₹0.70 Cr net book value) expected by Sep 30, 2026, and its P&L/cash impact
W3
Animal Welfare segment recovery after profit fell to ₹1.15 Cr in Q1FY27 from ₹2.34 Cr a year ago
Informational and educational content only. Not investment advice.